Answers are grounded in this paper and cite their sources.
No AccessJournal of Urology1 Apr 1979Improved Management of Non-Seminomatous Testis Tumors John P. Donohue, J. Michael Perez, and Laurence H. Einhorn John P. DonohueJohn P. Donohue More articles by this author , J. Michael PerezJ. Michael Perez More articles by this author , and Laurence H. EinhornLaurence H. Einhorn More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)56810-XAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Two contributions to the management of non-seminomatous germinal cell tumors of the testisare reviewed. First, a midline technique of extended retroperitoneal lymph node dissection has been developed, allowing good access to both renal suprahilar zones as well as the traditional hilar and infrahilar areas. This technique has been used at our medical center to stage embryonal carcinoma or teratocarcinoma of the testis in patients who had negative preoperative chest tomography. Of 58 consecutive patients seen from 1965 to 1975, 30 had stage A disease and 28 had stage B. All 30 patients with stage A disease survived (100 per cent) and 24 of 28 patients with stage B disease survived (86 per cent), for an over-all survival rate of 93 per cent. The second contribution relates to the development of a new combination chemotherapy protocol for patients with stage 0 disease. Preoperative stage C lesions are treated with platinum, vinblastine sulfate and bleomycin. Patients who achieve clearance of pulmonary tumors but who have anatomic or serologic evidence of persistent retroperitoneal tumor after this chemotherapy are later treated with retroperitoneal lymph node dissection. Of 12 such patients 6 have been rendered free of tumor and now enjoy complete remission. Furthermore, 33 of 50 patients (66 per cent) with disseminated stage C disease achieved initial complete remission using this drug combination. Of the 50 patients 26 remain in continuous complete remission with no evidence of disease for 2 to 4 years, 7 are alive and in partial remission and 17 are dead. Improved chemotherapy opens alternative methods to manage advanced testis cancer. © 1979 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byHomsy Y, Arrojo-Vila F, Khoriaty N and Demers J (2018) Yolk Sac Tumor of the Testicle: Is Retroperitoneal Lymph Node Dissection Necessary?Journal of Urology, VOL. 132, NO. 3, (532-535), Online publication date: 1-Sep-1984.Bracken R, Johnson D, Frazier O, Logothetis C, Trindade A and Samuels M (2018) The Role of Surgery Following Chemotherapy in Stage III Germ Cell NeoplasmsJournal of Urology, VOL. 129, NO. 1, (39-43), Online publication date: 1-Jan-1983.Whitmore W (2018) Editorial CommentJournal of Urology, VOL. 126, NO. 6, (752-752), Online publication date: 1-Dec-1981.MacDonald R, Turner A, McPhee M, Lakey W and Metcalfe J (2018) Management Of Nonseminomatous Testicular Cancer—A Total Community ExperienceJournal of Urology, VOL. 126, NO. 6, (750-752), Online publication date: 1-Dec-1981.Donohue J (2018) Guest Editorial: Testicular CancerJournal of Urology, VOL. 126, NO. 1, (59-59), Online publication date: 1-Jul-1981. Volume 121Issue 4April 1979Page: 425-428 Advertisement Copyright & Permissions© 1979 by The American Urological Association Education and Research, Inc.MetricsAuthor Information John P. Donohue More articles by this author J. Michael Perez More articles by this author Laurence H. Einhorn More articles by this author Expand All Advertisement PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Donohue et al. (1979) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: